Using sulforaphane from broccoli to prevent malignant mesothelioma
Official title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate BiomarkersTask Order Title: Sulforaphane for the Prevention of Malignant Mesothelioma
Funded at Research Inst of Fox Chase Can Ctr · NIH-10836806 · Data updated 2026-11-12
This study is looking at whether a natural compound from broccoli called sulforaphane can help prevent malignant mesothelioma, a serious cancer often caused by asbestos, especially in people who are at higher risk for cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 3, 2023 |
| Project end | May 2, 2026 |
| Funding year | 2023 |
| Award (this year) | $1,199,274 |
| NIH project number | 75N91019D00022-0-759102300003-1 |
| Project ID | NIH-10836806 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a history of asbestos exposure or those with a germline mutation of BAP1, which increases their risk for mesothelioma.
✕Less likely to help
Patients who do not have a history of asbestos exposure or genetic predisposition to mesothelioma may not benefit from this research.
What this research studies
This research investigates the potential of sulforaphane, a compound derived from broccoli, as a preventive treatment for malignant mesothelioma, a highly aggressive cancer linked to asbestos exposure. The study focuses on individuals at high risk, particularly those with a genetic predisposition to cancer, and aims to identify effective biomarkers for monitoring treatment efficacy. By targeting inflammatory mediators involved in cancer development, the research seeks to intercept tumor progression before it becomes malignant. Participants may receive sulforaphane over an extended period to assess its long-term safety and effectiveness.
Why it matters
Potential benefit: If successful, this research could provide a preventive strategy for individuals at high risk of developing malignant mesothelioma, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in using sulforaphane as a cancer preventive agent, indicating potential for success in this novel application.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Testa, Joseph — Research Inst of Fox Chase Can Ctr
- Study coordinator: Testa, Joseph
Related research
Other NIH-funded projects on the same topics.
-
National Mesothelioma Biobank expands patient biospecimen and data sharing for research
A national biobank collects blood, tissue, and clinical data from mesothelioma patients to help researchers develop better diagnostics and treatments.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Liquid multiomics to tailor systemic treatment for malignant pleural mesothelioma
Researchers are testing liquid biomarkers to help choose personalized treatments for people with malignant pleural mesothelioma.
-
New ways to make mesothelioma treatment work better
This project looks at whether common antidepressant drugs plus a drug that blocks Mcl-1 can help chemotherapy work better for people with malignant mesothelioma.
-
Targeting mitochondria to help immunotherapy work better for pleural mesothelioma
The team will try medicines that change cancer cell mitochondria to help immunotherapy work better for people with malignant pleural mesothelioma.
-
Tumor-targeted imaging and alpha-particle therapy for mesothelioma
This project develops an antibody-based imaging approach and a targeted alpha-particle therapy to find and kill mesothelioma tumors, including hard-to-treat sarcomatoid cases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.